Pharmacological Evaluation of Humanized Anti-Epidermal Growth Factor Receptor, Monoclonal Antibody h-R3, in Patients With Advanced Epithelial-Derived Cancer

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Journal of immunotherapy

• Publication date

  2003-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/00002371-200303000-00006PMID 12616105
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors as Anticancer Agents

  2012cited by this paper
• Evaluation of malignancy and the prognosis of esophageal cancer based on an immunohistochemical study (p53, E-cadherin, epidermal growth factor receptor)

  2006cited by this paper
• Antiproliferative, antiangiogenic and proapoptotic activity of h‐R3: A humanized anti‐EGFR antibody

  2002cited by this paper
• Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.

  2001cited by this paper
• Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder.

  2001cited by this paper
• A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor.

  2001cited by this paper
• Epidermal growth factor receptor biology (IMC-C225)

  2001cited by this paper
• Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis.

  2001cited by this paper
• Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer Is correlated with survival.

  2001cited by this paper
• Phase I Clinical Evaluation of a Neutralizing Monoclonal Antibody against Epidermal Growth Factor Receptor

  2001cited by this paper
• Epidermal growth factor receptor signaling and the invasive phenotype of ovarian carcinoma cells.

  2001cited by this paper
• Clinical trial with escalating doses of the antiepidermal growth factor receptor humanized monoclonal antibody EMD 72 000 in patients with advanced squamous cell carcinoma of the larynx and hypopharynx

  2001cited by this paper
• Abnormal Expression of Epidermal Growth Factor Receptor and c-erbB2 in Squamous Cell Carcinoma of the Cervix: Correlation with Human Papillomavirus and Prognosis

  2001cited by this paper
• Phase I Clinical Evaluation of a Neutralizing Monoclonal Antibody Against Epidermal Growth Factor Receptor in Advanced Brain Tumor Patients: Preliminary Study

  2001cited by this paper
• Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies.

  2001cited by this paper
• High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H.

  2001cited by this paper
• EGFR and cancer prognosis.

  2001cited by this paper
• Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer.

  2001cited by this paper
• Cutaneous side‐effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225

  2001cited by this paper
• Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

  2001cited by this paper
• Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment.

  2000cited by this paper
• [Zd 1839 "Iressa"].

  2000cited by this paper
• Co‐expression of epidermal growth factor receptor and transforming growth factor‐α predicts worse prognosis in breast‐cancer patients

  2000cited by this paper
• Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide.

  2000cited by this paper
• The EGF receptor family as targets for cancer therapy

  2000cited by this paper
• Safety and biodistribution of 99mTechnetium-labeled anti-CD44v6 monoclonal antibody BIWA 1 in head and neck cancer patients.

  2000cited by this paper
• Le ZD 1839 : « Iressa »

  2000cited by this paper
• Humanized versus murine anti-human epidermal growth factor receptor monoclonal antibodies for immunoscintigraphic studies.

  2000cited by this paper
• Detection of epidermal growth factor receptor in the serum of patients with cervical carcinoma.

  2000cited by this paper
• Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin.

  2000cited by this paper
• Immunohistochemical co-expression of c-erbb-2/Neu oncoprotein, altered tumour suppressor (p53) protein, EGF-R and EMA in histological subtypes of infiltrating duct carcinoma of the breast.

  1999cited by this paper
• Epidermal Growth Factor Protects Epithelial Cells against Fas-induced Apoptosis

  1999cited by this paper
• 99mTc-labeled antihuman epidermal growth factor receptor antibody in patients with tumors of epithelial origin: Part III. Clinical trials safety and diagnostic efficacy.

  1999influential reference
• Prognosis of esophageal squamous cell carcinoma: analysis of clinicopathological and biological factors

  1999cited by this paper
• Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma.

  1999cited by this paper
• Technetium-99m-labeled anti-EGF-receptor antibody in patients with tumor of epithelial origin: I. Biodistribution and dosimetry for radioimmunotherapy.

  1998cited by this paper
• Establishing a Link between Oncogenes and Tumor Angiogenesis

  1998cited by this paper
• In vitro invasion of small-cell lung cancer cell lines correlates with expression of epidermal growth factor receptor.

  1998cited by this paper
• Pharmacokinetics, biodistribution and dosimetry of 99mTc-labeled anti-human epidermal growth factor receptor humanized monoclonal antibody R3 in rats.

  1998cited by this paper
• Cell cycle: Molecular targets for diagnosis and therapy: Tumor suppressor genes and cell cycle progression in cancer

  1998cited by this paper
• Detection of epidermal growth factor receptor in the serum of gastric carcinoma patients

  1997cited by this paper
• Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity.

  1997cited by this paper
• Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors.

  1997cited by this paper
• Signal transduction pathways and their relevance in human astrocytomas

  1997cited by this paper
• Intratumoral infusion of the monoclonal antibody, mAb 425, against the epidermal-growth-factor receptor in patients with advanced malignant glioma

  1997cited by this paper
• Multiple infusions of anti-epidermal growth factor receptor (EGFR) monoclonal antibody (EMD 55,900) in patients with recurrent malignant gliomas.

  1996cited by this paper
• The detection of increased amounts of the extracellular domain of the epidermal growth factor receptor in serum during carcinogenesis in asbestosis patients.

  1994cited by this paper
• Harmonisation in Pharmacovigilance

  1994cited by this paper
• Gene amplification and overexpression of epidermal growth factor receptor in squamous cell carcinoma of the head and neck

  1992cited by this paper
• A new monoclonal antibody for detection of EGF‐receptors in western blots and paraffin‐embedded tissue sections

  1992cited by this paper
• A comparison of epidermal growth factor receptor (EGFR) and c‐erbB‐2 oncogene expression in head and neck squamous cell carcinomas

  1991cited by this paper
• Generacion y caracterizacion primaria de anticuerpos monoclonales contra el receptor del factor de crecimiento epidermico

  1989cited by this paper
• Expression of epidermal growth factor receptors in human brain tumors.

  1984cited by this paper
• Posterior probabilities for choosing a regression model

  1978cited by this paper

• Machine Learning-Based Survival Prediction in Cancer Patients Treated with Nimotuzumab: A Real-World Data Mining Approach

  2025cites this paper
• Nimotuzumab combined with docetaxel and cisplatin as first-line treatment for patients with recurrent or metastatic nasopharyngeal carcinoma: a multicenter, phase 2 trial

  2025cites this paper
• Concurrent chemoradiotherapy combined with nimotuzumab in stage III–IVa nasopharyngeal carcinoma: a retrospective analysis

  2022cites this paper
• Nimotuzumab Increases the Recovery Rate of Severe and Critical COVID-19 Patients: Evaluation in the Real-World Scenario

  2022cites this paper
• Nimotuzumab therapy in the treatment of pediatric central nervous system tumors: single-center experience

  2021cites this paper
• Modeling and Molecular Dynamic Simulation of F(ab′)2 Fragment of Nimotuzumab for Lung Cancer Diagnostics

  2021cites this paper
• A meta-analysis of randomized controlled studies

  2021cites this paper
• Nimotuzumab for Patients With Inoperable Cancer of the Head and Neck.

  2020cites this paper
• Nimotuzumab for Patients With Inoperable Cancer of the Head and Neck

  2020influential citation
• Semi-Mechanistic Pharmacokinetic Model to Guide the Dose Selection of Nimotuzumab in Patients with Autosomal Dominant Polycystic Kidney Disease

  2020cites this paper
• 177Lu radiolabeling and preclinical theranostic study of 1C1m-Fc: an anti-TEM-1 scFv-Fc fusion protein in soft tissue sarcoma

  2020cites this paper
• EGFR exon 19‐deletion aberrantly regulate ERCC1 expression that may partly impaired DNA damage repair ability in non‐small cell lung cancer

  2019cites this paper
• Pharmacokinetic Evaluation of Nimotuzumab in Patients With Autosomal Dominant Polycystic Kidney Disease

  2019cites this paper
• Systemic Delivery of Monoclonal Antibodies to the Central Nervous System for Brain Tumor Therapy

  2019cites this paper
• Supervivencia de pacientes con cáncer de pulmón con metástasis cerebral en Matanzas

  2019cites this paper
• Nimotuzumab with Concurrent Chemoradiation in Inoperable Locally Advanced Squamous Cell Carcinoma of Head and Neck: An Indian Experience

  2018cites this paper
• Additional induction chemotherapy to concurrent chemotherapy and intensity-modulated radiotherapy with or without nimotuzumab in first-line treatment for locoregionally advanced nasopharyngeal carcinoma: a propensity score matched analysis

  2018cites this paper
• Nimotuzumab combined with chemotherapy as first‐line treatment for advanced lung squamous cell carcinoma

  2018cites this paper
• Antitumor activity of nimotuzumab in combination with cisplatin in lung cancer cell line A549 in vitro.

  2018cites this paper
• Long-Term Use of Nimotuzumab in Combination With Intensity-Modulated Radiotherapy and Chemotherapy in the Treatment of Locoregionally Advanced Nasopharyngeal Carcinoma: Experience of a Single Institution.

  2018cites this paper
• Efficacy and Safety of Nimotuzumab Plus Radiotherapy With or Without Cisplatin-Based Chemotherapy in an Elderly Patient Subgroup (Aged 60 and Older) With Nasopharyngeal Carcinoma

  2018cites this paper
• Correction to: Characterization of the first fully human anti-TEM1 scFv in models of solid tumor imaging and immunotoxin-based therapy

  2018cites this paper
• microRNA-664 enhances proliferation, migration and invasion of lung cancer cells.

  2017cites this paper
• Treatment Outcomes of 257 Patients with Locoregionally Advanced Nasopharyngeal Carcinoma Treated with Nimotuzumab Plus Intensity-Modulated Radiotherapy with or without Chemotherapy: A Single-Institution Experience

  2017cites this paper
• Efficacy and safety of nimotuzumab with neoadjuvant chemotherapy followed by concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma

  2017cites this paper
• Developing chemotherapy for diffuse pontine intrinsic gliomas (DIPG).

  2017cites this paper
• Structure-Directed and Tailored Diversity Synthetic Antibody Libraries Yield Novel Anti-EGFR Antagonists.

  2017cites this paper
• Antibodies that Inhibit Specific Cellular Pathways in Gastric Cancer

  2017cites this paper
• Characterization of the first fully human anti-TEM1 scFv in models of solid tumor imaging and immunotoxin-based therapy

  2016cites this paper
• Current Molecular Targeted Therapy in Advanced Gastric Cancer: A Comprehensive Review of Therapeutic Mechanism, Clinical Trials, and Practical Application

  2016cites this paper
• New advances in targeted gastric cancer treatment.

  2016cites this paper
• Nimotuzumab, a humanized monoclonal antibody specific for the EGFR, in combination with temozolomide and radiation therapy for newly diagnosed glioblastoma multiforme: First results in Chinese patients

  2016cites this paper
• Nimotuzumab combined with concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: a retrospective analysis

  2016cites this paper
• Antibody h-R3-dendrimer mediated siRNA has excellent endosomal escape and tumor targeted delivery ability, and represents efficient siPLK1 silencing and inhibition of cell proliferation, migration and invasion

  2016cites this paper
• Nimotuzumab plus paclitaxel and cisplatin as the first line treatment for advanced esophageal squamous cell cancer: A single centre prospective phase II trial

  2016cites this paper
• Nimotuzumab enhances temozolomide‐induced growth suppression of glioma cells expressing mutant EGFR in vivo

  2016cites this paper
• Treatment outcome of nimotuzumab plus chemotherapy in advanced cancer patients: a single institute experience

  2016cites this paper
• A phase I study of nimotuzumab plus docetaxel in chemotherapy-refractory/resistant patients with advanced non-small-cell lung cancer.

  2016cites this paper
• EGFR monoclonal antibodies in locally advanced head and neck squamous cell carcinoma: What is their current role?

  2016cites this paper
• Semimechanistic model to characterize nonlinear pharmacokinetics of nimotuzumab in patients with advanced breast cancer

  2015cites this paper
• Nimotuzumab enhances radiation sensitivity of NSCLC H292 cells in vitro by blocking epidermal growth factor receptor nuclear translocation and inhibiting radiation-induced DNA damage repair

  2015cites this paper
• S-1 and Cisplatin With or Without Nimotuzumab for Patients With Untreated Unresectable or Metastatic Gastric Cancer

  2015cites this paper
• Role of EGFR Monoclonal Antibodies in the Management of Non-small Cell Lung Cancer.

  2015cites this paper
• Nimotuzumab in Treatment of Infiltrating Squamous Cell Carcinoma of Tongue

  2015cites this paper
• Cell and molecular biology of epidermal growth factor receptor.

  2014cites this paper
• Clinical management of advanced gastric cancer: the role of new molecular drugs.

  2014cites this paper
• Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer

  2014cites this paper
• Nimotuzumab, inmunoterapia eficaz para el tratamiento de tumores epiteliales malignos

  2014influential citation
• Immunoscintigraphy and radioimmunotherapy in Cuba: experiences with labeled monoclonal antibodies for cancer diagnosis and treatment (1993-2013).

  2014cites this paper
• Emerging molecular targets in the treatment of nasopharyngeal carcinoma

  2014cites this paper
• Nasopharyngeal Carcinoma: Management Strategies

  2014cites this paper
• Efficacy of Nimotuzumab Combined with Docetaxel–Cisplatin–Fluorouracil Regimen in Treatment of Advanced Oral Carcinoma

  2013cites this paper
• A phase I, pharmacokinetic and pharmacodynamic study of nimotuzumab in Japanese patients with advanced solid tumors

  2013cites this paper
• Pharmacokinetics Evaluation of Nimotuzumab in Combination with Doxorubicin and Cyclophosphamide in Patients with Advanced Breast Cancer

  2013cites this paper
• Personalized Management of Head & Neck Cancer

  2013cites this paper
• Chemotherapy and molecularly targeted therapies for previously untreated SCCHN

  2013cites this paper
• A retrospective analysis of nimotuzumab plus irinotecan as second-line treatment in advanced colorectal cancer

  2012cites this paper
• A phase I dose escalation study of Nimotuzumab in combination with concurrent chemoradiation for patients with locally advanced squamous cell carcinoma of esophagus

  2012cites this paper
• Targeting the Epidermal Growth Factor Receptor in the Treatment of Colorectal Cancer

  2012cites this paper
• Targeting the Epidermal Growth Factor Receptor in Solid Tumor Malignancies

  2012cites this paper
• Pharmacokinetics and Biodistribution Study of 7A7 Anti-Mouse Epidermal Growth Factor Receptor Monoclonal Antibody and Its F(ab')2 Fragment in an Immunocompetent Mouse Model

  2012cites this paper
• EGFR Monoclonal Antibodies in the Treatment of Squamous Cell Carcinoma of the Head and Neck: A View beyond Cetuximab

  2012cites this paper
• Radiosensitization induced by the anti-epidermal growth factor receptor monoclonal antibodies cetuximab and nimotuzumab in A431 cells

  2012cites this paper
• Radiofármacos en inmunocentelleografía y radioinmunoterapia

  2012cites this paper
• A phase I trial of gefitinib and nimotuzumab in patients with advanced non-small cell lung cancer (NSCLC).

  2012cites this paper
• The Use of Epidermal Growth Factor Receptor Monoclonal Antibodies in Squamous Cell Carcinoma of the Head and Neck

  2012cites this paper
• Nimotuzumab treatment of malignant gliomas

  2012cites this paper
• Trial Watch: Monoclonal antibodies in cancer therapy

  2012cites this paper
• Nimotuzumab, a novel monoclonal antibody to the epidermal growth factor receptor, in the treatment of non-small cell lung cancer.

  2011cites this paper
• Phase I clinical trial of the anti-EGFR monoclonal antibody nimotuzumab with concurrent external thoracic radiotherapy in Canadian patients diagnosed with stage IIb, III or IV non-small cell lung cancer unsuitable for radical therapy

  2011cites this paper
• A dose-escalation phase I trial of nimotuzumab, an antibody against the epidermal growth factor receptor, in patients with advanced solid malignancies

  2011cites this paper
• Don’t jump to rash conclusions

  2011cites this paper
• Nimotuzumab for pediatric diffuse intrinsic pontine gliomas

  2011cites this paper
• Biomarker and Therapeutic Studies of Antibodies and Small Molecules that Target EGFR

  2011cites this paper
• Effect of oxygen on tumor cell vaccine.

  2010cites this paper
• Effect of Oxygen on Tumor Cell Vaccine

  2010cites this paper
• Pharmacodynamic Trial of Nimotuzumab in Unresectable Squamous Cell Carcinoma of the Head and Neck: A SENDO Foundation Study

  2010cites this paper
• Nimotuzumab with chemoradiation confers a survival advantage in treatment-naïve head and neck tumors over expressing EGFR

  2010cites this paper
• The emerging role of nimotuzumab in the treatment of non-small cell lung cancer

  2010cites this paper
• FOLFOX-4 Regimen as a First-line Therapy for Cuban Patients with Metastatic Colorectal Cancer.

  2009cites this paper
• Nimotuzumab: a novel anti-EGFR monoclonal antibody that retains anti-EGFR activity while minimizing skin toxicity

  2009cites this paper
• Nimotuzumab in pediatric glioma.

  2009cites this paper
• Clinical experience with nimotuzumab in cuban pediatric patients with brain tumors, 2005 to 2007.

  2009cites this paper
• Nimotuzumab combined with radiotherapy reduces primary tumor and nodal volume in advanced undifferentiated nasopharyngeal carcinoma

  2009cites this paper
• Current situation of Panitumumab, Matuzumab, Nimotuzumab and Zalutumumab

  2008cites this paper
• Immunotherapy for head and neck cancer.

  2008cites this paper
• Phase I single-dose study of intracavitary-administered Nimotuzumab labeled with 188-Re in adult recurrent high-grade glioma

  2008cites this paper
• Biodistribution and internal dosimetry of the 188Re-labelled humanized monoclonal antibody anti-epidemal growth factor receptor, nimotuzumab, in the locoregional treatment of malignant gliomas

  2008cites this paper
• Enhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status

  2008cites this paper
• Cutaneous reactions related to systemic immunomodulators and targeted therapeutics.

  2008cites this paper
• Monoclonal Antibodies as Therapeutic Agents

  2008cites this paper
• Pharmacology of epidermal growth factor inhibitors.

  2007cites this paper
• Epidermal growth factor receptor inhibitors in colorectal cancer treatment: what's new?

  2007cites this paper
• Pharmacology of Epidermal Growth Factor Inhibitors

  2007cites this paper
• High Dose of h-R3, an Anti- Epidermal Growth Factor Receptor Monoclonal Antibody Labeled With 188 Rhenium Following Intravenous Injection into Rats

  2006cites this paper
• EGFR-targeting monoclonal antibodies in head and neck cancer.

  2006cites this paper
• Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: Report from a phase I/II trial

  2006cites this paper
• EGF-R small inhibitors and anti-EGF-R antibodies: advantages and limits of a new avenue in anticancer therapy.

  2006cites this paper
• Active antimetastatic immunotherapy in Lewis lung carcinoma with self EGFR extracellular domain protein in VSSP adjuvant

  2006cites this paper
• Targeting EGFR and HER‐2 receptor tyrosine kinases for cancer drug discovery and development

  2006cites this paper